Viewing nowGlyang Tablet 10mg (Empagliflozin)
Empagliflozin Amorphous 10mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

MFDS item code 202101825 · Approved 2021.02.24 · Insurance code 643705610
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medicine is used together with dietary therapy and exercise therapy to help control blood sugar in adult patients with type 2 diabetes mellitus. It can be used alone or in combination with other medications. Special precautions and effectiveness may be needed for patients with cardiovascular disease who do not have adequate blood sugar control, so it is essential to consult healthcare professionals. This medicine improves blood sugar control in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older adults No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment with this medicine is not recommended in adults aged 85 years or older because clinical experience is limited (see Precautions for Use, 4. General Precautions)
This medicine should not be used in certain patients. For example, it should not be administered to those who have an allergy to the active ingredient of this medicine, type 1 diabetes patients, patients with severe renal impairment, and those with lactose intolerance. In patients with impaired renal function, this medicine should be used cautiously, and if renal function continues to decline, the medication should be discontinued. Furthermore, this medicine may not be effective in patients with end-stage renal disease or those undergoing dialysis. It is indicated for limited use only in patients with mild to moderate heart failure and is not recommended for patients with severe heart failure. The risk of hypoglycemia may increase when used with insulin or medications that stimulate insulin secretion, so dosage adjustments may be necessary when used in combination with these drugs. During treatment, side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, and volume depletion may occur. Special caution is advised for elderly patients over 75 years, as they are at higher risk for fluid loss. Serious metabolic abnormalities such as ketoacidosis may occur; if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing develop, consult a physician immediately. This medicine may also cause liver damage, so patients with liver function impairment should be cautious. Blood pressure decreases and symptoms of dehydration may occur during treatment, making it essential to regularly monitor blood pressure and fluid status. Caution is advisable during driving or operation of machinery due to the risk of hypoglycemia. Pregnant women or those planning to become pregnant should avoid using this medicine, and nursing mothers should also refrain from taking it. Safety and efficacy have not been established in children under 18 years, so it is not used in this population. Although specific toxicity symptoms related to overdose have not been reported, appropriate treatment is required depending on the clinical condition. This medicine should be kept out of the reach of children, and caution is advised against transferring it to other containers as this may negatively affect the quality.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly closed container to protect it from air and moisture. Moreover, it is advisable to keep the medicine at room temperature between 1°C and 30°C, avoiding excessively hot or cold locations.
Light yellow, biconvex, round film-coated tablet
30 tablets/box [(*10 tablets/PTP*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin Amorphous 10mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Empagliflozin Amorphous 25mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

Empagliflozin Amorphous 25mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Empagliflozin Amorphous 10mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.